Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic Implant.
Autorzy:
Pons-Faudoa FP; Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.; School of Medicine and Health Sciences, Tecnologico de Monterrey, Monterrey 64710, NL, Mexico. Trani ND; Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.; College of Materials Sciences and Opto-Electronic Technology, University of Chinese Academy of Science (UCAS), Shijingshan, Beijing 100049, China. Sizovs A; Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA. Shelton KA; Department of Comparative Medicine, Michael E. Keeling Center for Comparative Medicine and Research, MD Anderson Cancer Center, Bastrop, TX 78602, USA. Momin Z; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA. Bushman LR; Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-Anschutz Medical Campus, Aurora, CO 80045, USA. Xu J; Center for Outcomes Research and DeBakey Heart and Vascular Center, Houston Methodist Research Institute, Houston, TX 77030, USA.; Weill Medical College of Cornell University, New York, NY 10065, USA. Lewis DE; Academic Institute Houston Methodist, Houston, TX 77030, USA. Demaria S; Department of Radiation Oncology, Weill Cornell Medicine, New York, NY 10065, USA.; Department of Pathology and Laboratory of Medicine, Weill Cornell Medicine, New York, NY 10065, USA. Hawkins T; Gilead Sciences, Inc., Foster City, CA 94404, USA. RooneyJF; Gilead Sciences, Inc., Foster City, CA 94404, USA. Marzinke MA; Departments of Pathology and Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA. Kimata JT; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA. Anderson PL; Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-Anschutz Medical Campus, Aurora, CO 80045, USA. Nehete PN; Department of Comparative Medicine, Michael E. Keeling Center for Comparative Medicine and Research, MD Anderson Cancer Center, Bastrop, TX 78602, USA.; The University of Texas MD Anderson Cancer Center UTH Health Graduate School of Biomedical Sciences, Houston, TX 77030, USA. Arduino RC; Division of Infectious Diseases, Department of Internal Medicine, McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, TX 77030, USA. Sastry KJ; Department of Comparative Medicine, Michael E. Keeling Center for Comparative Medicine and Research, MD Anderson Cancer Center, Bastrop, TX 78602, USA.; Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Grattoni A; Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.; Department of Surgery, Houston Methodist Research Institute, Houston, TX 77030, USA.; Department of Radiation Oncology, Houston Methodist Research Institute, Houston, TX 77030, USA.
Pokaż więcej
Źródło:
Pharmaceutics [Pharmaceutics] 2020 Oct 17; Vol. 12 (10). Date of Electronic Publication: 2020 Oct 17.
Effective use of pre-exposure prophylaxis (PrEP) Among stimulant users with multiple condomless sex partners: a longitudinal study of men who have sex with men in Los Angeles.
Autorzy:
Goodman-Meza D; a Division of Infectious Diseases, David Geffen School of Medicine at UCLA , Los Angeles , CA , USA. Beymer MR; a Division of Infectious Diseases, David Geffen School of Medicine at UCLA , Los Angeles , CA , USA.; b Health and Mental Health Services, Los Angeles LGBT Center , Los Angeles , CA , USA. Kofron RM; c UCLA Center for Clinical AIDS Research & Education (CARE) , Los Angeles , CA , USA. Amico KR; d Department of Health Behavior and Health Education, University of Michigan School of Public Health , Ann Arbor , MI , USA. Psaros C; e Behavioral Medicine Program, Department of Psychiatry, Massachusetts General Hospital , Boston , MA , USA. Bushman LR; f Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado , Aurora , CO , USA. Anderson PL; f Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado , Aurora , CO , USA. Bolan R; b Health and Mental Health Services, Los Angeles LGBT Center , Los Angeles , CA , USA. Jordan WC; g OASIS Clinic, Charles R. Drew University of Medicine and Science , Los Angeles , CA , USA. RooneyJF; h Gilead Sciences , Foster City , CA , USA. Wohl AR; i Division of HIV and STD Programs, Los Angeles County Department of Public Health , Los Angeles , CA , USA. Landovitz RJ; a Division of Infectious Diseases, David Geffen School of Medicine at UCLA , Los Angeles , CA , USA.; c UCLA Center for Clinical AIDS Research & Education (CARE) , Los Angeles , CA , USA.
Pokaż więcej
Źródło:
AIDS care [AIDS Care] 2019 Oct; Vol. 31 (10), pp. 1228-1233. Date of Electronic Publication: 2019 Mar 20.
Typ publikacji:
Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
